Sanusi Muhammad, Momin Elina S, Mannan Vijayalakshmi, Kashyap Tejasvi, Pervaiz Muhammad Ahad, Akram Aqsa, Khan Asma A, Elshaikh Abeer O
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
General Practice, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Cureus. 2022 Jun 20;14(6):e26130. doi: 10.7759/cureus.26130. eCollection 2022 Jun.
Peripartum cardiomyopathy (PPCM) is a rare but debilitating form of heart failure that affects pregnant women. Although PPCM has a high rate of complete resolution, some patients often have a progressive disease and develop significant morbidity and mortality. Making an accurate prediction of outcomes and identifying those patients at the highest risk has proven difficult over the years. This study aimed to establish if we can use echocardiographic parameters and biomarkers as reliable indicators of prognosis. A predetermined systematic search strategy was employed in four databases: PubMed, Google Scholar, Science Direct, and Cochrane Library to include articles from the last 15 years (January 2007 to January 2022). Data from 12 studies were synthesized and included in this study. Although no parameter proved consistent in all the studies, echocardiographic parameters, including strain profiles and biomarkers, proved significant in the prognostication of patients with PPCM in the various studies evaluated. Therefore, a holistic approach is still needed in the risk stratification of patients with PPCM. Future studies should evaluate these parameters as well as clinical characteristics in a larger cohort study with a long follow-up period of more than one year in order to potentially develop prognostic score criteria that can be used to accurately identify those patients at the highest risk of developing severe disease or death to allow for timely and targeted therapies to improve outcomes in these patients.
围产期心肌病（PPCM）是一种影响孕妇的罕见但使人衰弱的心力衰竭形式。尽管PPCM有很高的完全缓解率，但一些患者往往病情进展，出现显著的发病率和死亡率。多年来，准确预测预后并识别那些风险最高的患者一直很困难。本研究旨在确定我们是否可以使用超声心动图参数和生物标志物作为可靠的预后指标。我们在四个数据库（PubMed、谷歌学术、科学Direct和考科蓝图书馆）中采用了预先确定的系统检索策略，以纳入过去15年（2007年1月至2022年1月）的文章。对12项研究的数据进行了综合并纳入本研究。尽管在所有研究中没有一个参数被证明是一致的，但在评估的各项研究中，包括应变曲线和生物标志物在内的超声心动图参数在PPCM患者的预后评估中被证明具有重要意义。因此，在PPCM患者的风险分层中仍需要一种整体方法。未来的研究应该在一项随访期超过一年的更大队列研究中评估这些参数以及临床特征，以便有可能制定出可用于准确识别那些发生严重疾病或死亡风险最高的患者的预后评分标准，从而能够进行及时且有针对性的治疗，以改善这些患者的预后。
